Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2024-518013-25-00
Authorised, recruiting Phase II

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis

2024-518013-25-00 · tracked via the Priya Life Science EU tracker
Sponsor
AbbVie Deutschland GmbH & Co. KG
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
10/03/2026
Enrollment target
86
Sites
Greece, Italy, Sweden, Germany, Portugal, Spain, France, Hungary, Poland, Bulgaria, Romania

Condition studied

Idiopathic Pulmonary Fibrosis

Investigational medicinal product(s)

Placebo for ABBV-142

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Absolute change from baseline in forced vital capacity (mL) at Week 24.

Endpoint detail

Absolute change from baseline in FVC (mL) at Week 52., Relative change from baseline in FVC (mL) at Week 24., Relative change from baseline in FVC (mL) at Week 52., Absolute and relative change from Baseline in FVC % predicted at Week 24., Absolute and relative change from Baseline in FVC % predicted at Week 52., Time to first ≥ 10% absolute decline in FVC% predicted., Time to first ≥ 5% absolute decline in FVC% predicted.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-518013-25-00 on CTIS ↗ ← All trials in the EU